Human TGF-β1 ELISA Kit

Principle of the Assay

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for TGF-β1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any TGF-β1 present is bound by the immobilized antibody. Following incubation unbound samples are removed during a wash step, and then a detection antibody specific for TGF-β1 is added to the wells and binds to the combination of capture antibody- TGF-β1 in sample. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Following incubation and wash steps a substrate is added. A coloured product is formed in proportion to the amount of TGF-β1 present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450nm. A standard curve is prepared from seven TGF-β1 standard dilutions and TGF-β1 sample concentration determined.

For Use with serum, plasma and cell culture supernatants. For Research Use Only. Not for use in diagnostic procedures.

Target Information

Transforming growth factor (TGF), a ‘factor’ that promoted the transformation of cultured fibroblasts into a tumor-like phenotype, was subsequently found to be more of a tumor suppressor than tumor promoter and to be a mixture of two proteins, TGF-α and TGF-β. These molecules are members of a superfamily that includes TGF-β1 through 5, bone morphogenic proteins, activins and inhibins. It plays a critical role in cellular growth, development, differentiation, proliferation, extracellular matrix (ECM) synthesis and degradation, control of mesenchymal-epithelial interactions during embryogenesis, immune modulation, apoptosis, cell cycle progression, angiogenesis, adhesion and migration and leukocyte chemotaxis.

Originally, TGF-β1 was separated from platelets and later found that TGF-β1 can be expressed in many organizations. Human TGF-β1 is a 25kDa, disulfide-linked, non-glycosylated homodimer. Biological activity of TGF-β1 is regulated by a number of receptors, including receptor I (53-65KD), receptor II (83-110KD), receptor III (250-310KD), receptor-IV (60KD) and receptor V (400KD).

TGF-β1 is the key mediator in the pathophysiology of tissue repair and human fibrogenesis: balance between production and degradation of type I collagen, and fibrosis and scarring in organ and tissue. TGF-β1 exhibits important immunoregulatory features of partially adverse character: TGF-β1 inhibits B and T cell proliferation, differentiation and antibody production as well as maturation and activation of macrophages. TGF-β1 is synthesized, with only a few exceptions, by virtually all cells, and TGF receptors are expressed by all cells. TGF-β affects nearly every physiological process in some way; its systemic and cell-specific activities are too complicated to review here. There are, however, three fundamental activities: TGF-β1 modulates cell proliferation, generally as a suppressor; TGF-β1 enhances the deposition of extracellular matrix through promotion of synthesis and inhibition of degradation; TGF-β1 is immunosuppressive through a variety of mechanisms. The specific action of TGF-β on a particular cell depends on the exact circumstances of that cell’s environment.

Materials Supplied

Storage

Performance Characteristics

Factors assayed for cross-reactivity

Data Analysis Assistance

We have partnered with MyAssays to offer you an easy to use and versatile tool to analyze the data you receive using our ELISA Kit. Click the link below to be directed to the data analysis tool provided by MyAssays specifically for BSKH1021.

https://www.myassays.com/bioss-human-tgf-%ce%b21-elisa-kit.assay